


# Diversification Update at 30/09/2012

TOBAM's Diversification Ratio (DR)<sup>1</sup> measures to what extent a portfolio is diversified. The DR<sup>2</sup> (square of the diversification ratio) corresponds to the number of independent degrees of freedom in a particular portfolio - or the number of independent variables at work. As the table shows, the "broad market" indices leave diversification on the table. In addition to a snapshot of each market's  $DR^2$ , the table shows the  $DR^2$  of a welldiversified portfolio, and the fraction of available diversification used by the index.

	DR <sup>2</sup> - Index diversification	DR <sup>2</sup> - Maximum diversification	% diversification used by index
MSCI EMU	1.82	5.19	36%
MSCI US	2.16	5.75	38%
MSCI UK	2.12	3.66	58%
MSCI Japan	2.62	9.06	29%
MSCI World	2.66	7.29	36%
MSCI Australia	2.02	4.33	47%
MSCI Canada	2.79	6.86	41%
MSCI Emerging <sup>2</sup>	3.35	4.79	70%

# **Canadian Equities: Diversification and performance**

Since its launch in April 2011, the Most Diversified Portfolio for Canadian Equities has provided significant outperformance while reducing volatility, by maximizing diversification:



# Protection in down market:

- Since its inception through the end of 2011, the strategy protected on the downside: the Canadian Equity market returned -19.86%, but the AB Canada strategy protected investors on the downside, improving performance by +7.79%.
- The strategy reduced volatility by 26% for the period.

#### Performance in up market:


- For the year to date period through September 30, Canadian Equities rebounded, particularly in the third quarter. The Anti-Benchmark Equity strategy uncovered more diversifying opportunities than the benchmark over this period, returning 12.28% compared to 8.37% for the index, and as a result offered a significant performance advantage, outperforming the MSCI Canada index by +3.91%.
- The Anti-Benchmark Canada strategy also reduced volatility by 21% for the period.

<sup>&</sup>lt;sup>1</sup>TOBAM's Diversification Ratio measures a portfolio's or index's diversification. It is supported by original research and is based on a mathematical definition of diversification. TOBAM's "Anti-Benchmark" Most Diversified Portfolio® maximizes this Diversification Ratio. Maximizing diversification within a universe of securities provides a result closer to the true market risk premium from that universe. "Maximum Diversification®" and "MaxDiv®" are registered trademarks of TOBAM. <sup>2</sup> The Anti-Benchmark Emerging Markets Equity strategy filters the reference index to the 200 largest market capitalizations.



# Canadian equities: a concentrated market...


The following graph breaks down the risk contributors for the MSCI Canada index and for the corresponding Anti-Benchmark portfolio. It is clear that the benchmark is highly concentrated in Energy, Materials and Financials, while Anti-Benchmark portfolio exposures are spread more uniformly:



The diversification gap between the MSCI Canada and the AB Canada portfolio thus comes as no surprise. Each portfolio's DR<sup>2</sup>s, corresponding to the number of independent degrees of freedom in the portfolio, indicate that the "broad market" index leaves diversification on the table. The difference between the DR<sup>2</sup> for the AB Canada and for the cap-weighted benchmark is particularly striking: the AB Canada taps into almost three times as much diversification as the benchmark. AB Canada's DR<sup>2</sup> of 6.86 is impressive compared to only 2.79 for the MSCI Canada: the cap-weighted benchmark accesses only 41% of available diversification.

# ...that includes the same risk concentrations as emerging markets:


Most investors would not question the benefits of allocating to Emerging Markets for diversification. However, the risk drivers for market cap-weighted Emerging Markets Equities are similar to those for Canadian equities. Both markets are focused on Financials, Energy and Materials:





# Anti-Benchmark: delivering less risk and more return

From June 29, 2011 (inception date of the Anti-Benchmark Emerging Markets strategy) to September 28, 2012, both the Anti-Benchmark Emerging Markets equity and Canada equity strategies significantly reduced risk and improved returns vs. their respective market cap-weighted MSCI benchmarks:



# Anti-Benchmark: diversified and diversifying

Combining Anti-Benchmark strategies with MSCI index strategies can also be beneficial. The following table compares the effects of combining a Canadian equities portfolio invested passively (MSCI index) with an allocation to emerging markets equities, either via the MSCI EM index or the Anti-Benchmark EM. For illustration purposes, a combination of both AB Canada and AB EM equity strategies is included:





# For more information

TOBAM is an asset management company offering innovative investment capabilities whose aim is to maximize diversification. TOBAM's flagship Anti-Benchmark® strategies, supported by original research and a mathematical definition of diversification, provide clients with diversified core equity exposure, both globally and in domestic markets. FTSE also publishes the FTSE TOBAM Maximum Diversification Index Series based on the Anti-Benchmark equity portfolio construction methodology. The company manages over \$2.6 billion via its Anti-Benchmark strategies for institutional clients worldwide. Its team includes seventeen financial professionals.

# **Contacts:**

Head of Business Development Christophe Roehri +33 1 53 23 41 60 Christophe.Roehri@tobam.fr

Business Development Laura Vu Thien +33 1 53 23 41 65 Laura.VuThien@tobam.fr

Client Service Elizabeth Breaden +33 1 53 23 41 56 ClientService@tobam.fr

### **TOBAM Marketing Partners**

**Global Distribution - Amundi** Astrid Gambihler +33 1 76 37 85 35 <u>astrid.gambihler@amundi.com</u>

Nordics - Paxstone Capital LLP Kasper Kemp Hansen +45 36 95 97 00 kasper.hansen@paxstone.com

#### Canada - Investeam

Nancy Nightingale +1 416 860 9490 nancy.nightingale@investeam.ca

# Australia & NZ - Phoenix Capital Advisory Ltd.

Mark Jackson <u>mark.jackson@phoenixcap.com.au</u> Matthew Wormald <u>matt.wormald@phoenixcap.com.au</u> +612 8705 5473

# **Disclaimers**

This document is intended for professional investors only. This document is confidential and may not be reproduced in any form without the express permission of TOBAM and to the extent that it is passed on, care must be taken to ensure that any reproduction is in a form which accurately reflects the information presented here. While TOBAM believes that the information is correct at the date of production, no warranty or representation is given to this effect and no responsibility can be accepted by TOBAM to the recipient of this document or end users for any action taken on the basis of the information contained herein. We do not represent that this information, including any third party information, is accurate or complete and it should not be relied upon as such. No reliance may be placed for any purpose on the information and opinions contained in this document or their accuracy or completeness. Opinions expressed herein reflect the opinion of TOBAM and are subject to change without notice. This document is for information purposes and does not constitute advice or a recommendation to enter into any transaction or an offer or an agreement, or a solicitation of an offer or an agreement, to enter into any transaction, nor shall it or the fact of its distribution form the basis of, or be relied on in connection with, any contract for the same. The fund(s) that may be mentioned in this email or document may not be eligible for sale in some states or countries and they may not be suitable for all types of investors. Before entering into any transaction, you should consider the suitability of the transaction to your particular circumstances and independently review (with your professional advisers as necessary) the specific financial risks as well as the legal, regulatory, credit, tax and accounting consequences of entering into such transaction. The value and the income produced by a strategy may be adversely affected by exchange rates, interest rates, or other factors so that an investor may get back less than he or she invested. Past performance is not indicative of future results. **Copyrights:** All text, graphics, interfaces, logos and artwork, including but not limited to the design, structure, selection, coordination, expression, "look and feel" and arrangement contained in this presentation, are owned by TOBAM and are protected by copyright and various other intellectual property rights and unfair competition laws. **Trademarks:** "TOBAM," "MaxDiv," "Maximum Diversification," "Diversification, Ratio," "Most Diversified Portfolio," "Most Diversified Portfolios," "MDP" and "Anti-Benchmark" are registered trademarks. The absence of a product or service name from this list does not constitute a waiver of TOBAM trademark or other intellectual property rights concerning that name.

**Patents:** The Anti-Benchmark, MaxDiv and Maximum Diversification strategies, methods and systems for selecting and managing a portfolio of securities, processes and products are patented or patent pending. **Knowledge, processes and strategies:** The Anti-Benchmark, MaxDiv and Maximum Diversification strategies, methods and systems for selecting and managing a portfolio of securities, processes and products are protected under unfair competition, passing-off and misappropriation laws. **Terms of use:** TOBAM owns all rights to, title to and interest in TOBAM products and services, marketing and promotional materials, trademarks and Patents, including without limitation all associated Intellectual Property Rights. Any use of the intellectual property, knowledge, processes and strategies of TOBAM for any purpose and under any form (known and/or unknown) in direct or indirect relation with financial products including but not limited to certificates, indices, notes, bonds, OTC options, warrants, mutual funds, ETFs and insurance policies (i) is strictly prohibited without TOBAM's prior written consent and (ii) requires a license.

This document is issued by TOBAM which is authorized and regulated by the Autorité des Marchés Financiers ("AMF"). @ TOBAM 2012